A Phase 3, multicenter, randomized, double-blind, 48-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized high-risk participants with COVID-19

Primary Objective

The SCORPIO-HR Study is a clinical research study looking at an investigational drug for COVID-19 in people who have tested positive and whether it can help resolve COVID-19 symptoms faster and reduce COVID-19 symptoms that persist for several months (called “long COVID”).

Is this Study for You?

Let's Get Started!


Participation in the study will last about 24 weeks and participants will have at least 8 study visits. Participants will be randomly assigned to take the investigational drug or a placebo as 3 tablets on the first day of study treatment followed by 1 tablet a day for 4 days.




You, or someone you know, may be able to take part if you/they: -are 18 years of age or older -have had a positive diagnosis of COVID-19 within the past 72 hours (3 days) -are experiencing COVID-19 symptoms such as coughing, shortness of breath, feeling feverish, fatigue, nausea, chills, headaches, or sore throat, among others, within the past 3 days (with one or more symptoms ongoing).

Type of Study






Principal Investigator
Photograph of Thomas Campbell,  MD

Thomas Campbell, MD

Study ID

Protocol Number: 22-0587

More information available at ClinicalTrials.gov: NCT05305547

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers